France
ALTEVAX
ALTEVAX develops an innovative and disruptive immunotherapy platform for the treatment of cancer. It is based on synthetic melanin, a non-toxic and versatile biopolymer adjuvant, that can be combined with a wide range of antigenic peptides.
CREATION
EMPLOYEES
CITY
Paris
DEVELOPMENT LEVEL
FUNDRAISING
FUNDRAISING AMOUNT
5.5m EUR
